Retraction: Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21 (Obesity, (2014), 22 (705–712), 10.1002/oby.20559);Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21

Obesity

Volumn 22, Issue 3, 2014, Pages 705-712

  Hinds, Terry D ^d   Sodhi, Komal ^a   Meadows, Charles ^a   Fedorova, Larisa ^d   Puri, Nitin ^d   Kim, Dong Hyun ^a   Peterson, Stephen J ^b   Shapiro, Joseph ^a   Abraham, Nader G ^a   Kappas, Attallah ^c  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAT DROPLET; FATTY ACID SYNTHASE; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; GLUCOSE TRANSPORTER 1; GLYCOGEN; HEME; HEME OXYGENASE; HEME OXYGENASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTOPORPHYRIN COBALT; STANNSOPORFIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY LIVER; GLYCOGEN ANALYSIS; LIPID STORAGE; LIPOGENESIS; LIVER LEVEL; MALE; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; WEIGHT GAIN;

MUS;

ADIPOSITY; ANIMALS; FATTY LIVER; FIBROBLAST GROWTH FACTORS; GLUCOSE TRANSPORTER TYPE 1; GLYCOGEN; HEME; HEME OXYGENASE-1; LEPTIN; LIVER; MALE; MEMBRANE PROTEINS; MESOPORPHYRINS; MICE; MICE, OBESE; OBESITY; PPAR ALPHA; PROTOPORPHYRINS; TIN COMPOUNDS; TRANSCRIPTION FACTORS; WEIGHT GAIN;

EID: 84895805263     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.23735     Document Type: Erratum

References (39)

1. Krahenbuhl L, Lang C, Ludes S, et al. Reduced hepatic glycogen stores in patients with liver cirrhosis. Liver Int 2003; 23: 101-109.
2. Estall JL, Ruas JL, Choi CS, et al. PGC-1alpha negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erb(alpha) axis. Proc Natl Acad Sci USA 2009; 106: 22510-22515.
3. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK,. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104: 861-867.
4. Abraham NG, Kappas A,. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60: 79-127.
5. Cao J, Peterson SJ, Sodhi K, et al. Heme oxygenase gene targeting to adipocytes attenuates adiposity and vascular dysfunction in mice fed a high-fat diet. Hypertension 2012; 60: 467-475.
6. Nicolai A, Li M, Kim DH, et al. Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats. Hypertension. 2009; 53: 508-515.
7. Peterson SJ, Kim DH, Li M, et al. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res 2009; 50: 1293-1304.
8. Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007; 297: 1362-1373.
9. Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003; 38: 414-418.
10. Cao J, Sodhi K, Inoue K, et al. Lentiviral-human heme oxygenase targeting endothelium improved vascular function in angiotensin ii animal model of hypertension. Hum Gene Ther. 2011; 22: 271-282.
11. Berberat PO, Katori M, Kaczmarek E, et al. Heavy chain ferritin acts as an antiapoptotic gene that protects livers from ischemia reperfusion injury. FASEB J 2003; 17: 1724-1726.
12. Li M, Kim DH, Tsenovoy PL, et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008; 57: 1526-1535.
13. Kruger AL, Peterson S, Turkseven S, et al. D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 2005; 111: 3126-3134.
14. Kumar N, Solt LA, Wang Y, et al. Regulation of adipogenesis by natural and synthetic REV-ERB ligands. Endocrinology 2010; 151: 3015-3025.
15. Raghuram S, Stayrook KR, Huang P, et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat Struct Mol Biol 2007; 14: 1207-1213.
16. Potthoff MJ, Inagaki T, Satapati S, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 2009; 106: 10853-10858.
17. Preitner N, Damiola F, Lopez-Molina L, et al. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 2002; 110: 251-260.
18. Wu N, Yin L, Hanniman EA, Joshi S, Lazar MA,. Negative feedback maintenance of heme homeostasis by its receptor, Rev-erbalpha. Genes Dev 2009; 23: 2201-2209.
19. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789.
20. Chau MD, Gao J, Yang Q, Wu Z, Gromada J,. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci USA 2010; 107: 12553-12558.
21. Stienstra R, Mandard S, Patsouris D, Maass C, Kersten S, Muller M,. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology 2007; 148: 2753-2763.
22. Cao J, Puri N, Sodhi K, Bellner L, Abraham NG, Kappas A,. Apo A1 mimetic rescues the diabetic phenotype of HO-2 knockout mice via an increase in HO-1 adiponectin and LKBI signaling pathway. Int J Hypertens 2012; 2012: 628147.
23. Kim BH, Won YS, Kim EY, et al. Phenotype of peroxisome proliferator-activated receptor-alpha(PPARalpha)deficient mice on mixed background fed high fat diet. J Vet Sci 2003; 4: 239-244.
24. Yachie A, Niida Y, Wada T, et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 1999; 103: 129-135.
25. Jeney V, Balla J, Yachie A, et al. Pro-oxidant and cytotoxic effects of circulating heme. Blood 2002; 100: 879-887.
26. Takamiya R, Murakami M, Kajimura M, et al. Stabilization of mast cells by heme oxygenase-1: an anti-inflammatory role. Am J Physiol Heart Circ Physiol 2002; 283: H861-H870.
27. Nath KA, Haggard JJ, Croatt AJ, Grande JP, Poss KD, Alam J,. The indispensability of heme oxygenase-1 in protecting against acute heme protein-induced toxicity in vivo. Am J Pathol 2000; 156: 1527-1535.
28. Biberstine-Kinkade KJ, DeLeo FR, Epstein RI, LeRoy BA, Nauseef WM, Dinauer MC,. Heme-ligating histidines in flavocytochrome b(558): identification of specific histidines in gp91(phox). J Biol Chem 2001; 276: 31105-31112.
29. Finegold AA, Shatwell KP, Segal AW, Klausner RD, Dancis A,. Intramembrane bis-heme motif for transmembrane electron transport conserved in a yeast iron reductase and the human NADPH oxidase. J Biol Chem 1996; 271: 31021-31024.
30. Chang SH, Barbosa-Tessmann I, Chen C, Kilberg MS, Agarwal A,. Glucose deprivation induces heme oxygenase-1 gene expression by a pathway independent of the unfolded protein response. J Biol Chem 2002; 277: 1933-1940.
31. Quan S, Kaminski PM, Yang L, et al. Heme oxygenase-1 prevents superoxide anion-associated endothelial cell sloughing in diabetic rats. Biochem Biophys Res Commun 2004; 315: 509-516.
32. Abraham NG, Kushida T, McClung J, et al. Heme oxygenase-1 attenuates glucose-mediated cell growth arrest and apoptosis in human microvessel endothelial cells. Circ Res 2003; 93: 507-514.
33. Issan Y, Hochhauser E, Kornowski R, et al. Endothelial progenitor cell function inversely correlates with long-term glucose control in diabetic patients: association with the attenuation of the heme oxygenase-adiponectin axis. Can J Cardiol 2012; 28: 728-736.
34. Kawamura K, Ishikawa K, Wada Y, et al. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol 2005; 25: 155-160.
35. Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC,. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001; 87: 1196-1200.
36. Basaranoglu M, Basaranoglu G, Senturk H,. From fatty liver to fibrosis: a tale of "second hit". World J Gastroenterol 2013; 19: 1158-1165.
37. Bijland S, Mancini SJ, Salt IP,. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci (Lond) 2013; 124: 491-507.
38. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB,. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 2006; 55: 2562-2570.
39. Yu J, Chu ES, Wang R, et al. Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice. Gastroenterology 2010; 138: 694-704, 704.